Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ABBOTINDIA.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ABBOTINDIA.BO and 80,000+ other tickers.
See exactly how ABBOTINDIA.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ABBOTINDIA.BO and 80,000+ other tickers.
Abbott India Limited is an Indian pharmaceutical enterprise primarily engaged in the development and distribution of a diverse range of medicinal products. Its extensive portfolio addresses critical therapeutic areas such as women's health, gastroenterology, metabolic disorders, central nervous system conditions, and vaccines. The company also offers multi-specialty solutions for insomnia, vitamin D deficiency, pre-term labor, and pain management, alongside anti-infectives, cardio-diabetic treatments, hormones, respiratory care, hepatic products, and consumer health items. Founded in 1910…
No recent news available.